MidWestOne Financial Group Inc. Has $346,000 Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

MidWestOne Financial Group Inc. raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 777 shares of the medical equipment provider’s stock after buying an additional 40 shares during the period. MidWestOne Financial Group Inc.’s holdings in Intuitive Surgical were worth $346,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. Vanguard Group Inc. lifted its position in shares of Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after buying an additional 272,741 shares during the period. Capital World Investors lifted its holdings in Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after buying an additional 73,634 shares during the period. Jennison Associates LLC lifted its holdings in Intuitive Surgical by 4.6% in the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after buying an additional 198,483 shares during the period. Finally, Fisher Asset Management LLC lifted its holdings in Intuitive Surgical by 1.9% in the fourth quarter. Fisher Asset Management LLC now owns 4,488,048 shares of the medical equipment provider’s stock valued at $1,514,088,000 after buying an additional 82,652 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In other news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares in the company, valued at approximately $145,113.45. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $446.60, for a total value of $167,921.60. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,458,979.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. The disclosure for this sale can be found here. In the last 90 days, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by insiders.

Intuitive Surgical Price Performance

Shares of ISRG opened at $479.18 on Friday. The firm has a 50-day moving average of $473.03 and a 200-day moving average of $428.49. The company has a market cap of $169.97 billion, a PE ratio of 86.49, a price-to-earnings-growth ratio of 5.39 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.18 EPS. Analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on ISRG. Robert W. Baird increased their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Barclays increased their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. BTIG Research increased their price objective on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. increased their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Finally, Piper Sandler increased their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.